News
ATOX to Supply Bayer with Galli EoTM for Prostate Cancer Study.
On 17th May 2023, ATOX entered into an agreement with Bayer Yakuhin Co., Ltd. to supply IRE ELiT’s 68Ge/68Ga generator “Galli EoTM”.
Interview of ATOX's president Toshikazu Yaguchi was published in "Newsweek International".
Toshikazu Yaguchi, ATOX's president, was interviewed by the UK news agency, The Worldfolio on June 12, 2023. The article of the interview was published in "Newsweek International" issued on September 8 and also The Worldfolio web site.
Interview of ATOX's president Toshikazu Yaguchi was published in "Newsweek International".
Toshikazu Yaguchi, ATOX's president, was interviewed by the UK news agency, The Worldfolio on April 7, 2022. The article of the interview was published in "Newsweek International" issued on June 17 and also The Worldfolio web site.
Joint Press Conference Held by QST and ATOX for Brain-dedicated PET (Vrain) Launch
Press conference for Brain-dedicated PET (product name "Vrain") was held at the National Institute for Quantum and Radiological Science and Technology (hereinafter called QST) on January 18, 2022. From QST, Dr. Takashi Nakano (Managing Director of Quantum Life and Medical Science Directorate) and Dr. Taiga Yamaya (Group Leader of Imaging Physics Group), and from ATOX, President Toshikazu Yaguchi and Executive Managing Director Satoshi Ueda attended the conference, and the world's first hemispherical PET system was introduced.
Video for Aerial Vehicle Released
Training session was held for operating aerial vehicle towards the decontamination work of operation floor in nuclear reactor building in Unit 2 of Fukushima Dai-ichi Nuclear Power Station. Video is now available on TEPCO's website "Photo & Video Library".
Business Transfer Agreement on Nuclear Power Business
ATOX and Kawasaki Heavy Industries concluded a Business Transfer Agreement. ATOX takes over KHI's nuclear power business.
On July 17, 2020, ATOX Signed MOU with Telix Japan to Supply IRE ELiT 68Ge/68Ga Generator for Phase I Study of 68Ga-PSMA-11 Prostate Cancer Diagnostic Imaging Kit
ATOX signed MOU with Telix Pharmaceuticals Japan (hereinafter called Telix Japan) to supply IRE ELiT 68Ge/68Ga generator "Galli Eo ®" for phase I study of Prostate cancer diagnostic imaging.
ATOX and Orano renew joint venture agreement
On July 18, 2019, Atox and Orano renewed their joint venture agreement. ANADEC decides to step up its commitment to help Japan’s D&D business. Read more
“Fukushima Marché” held at ATOX head office in Shiba today
As part of its efforts to support the reconstruction of Fukushima, ATOX hosted a “Fukushima Marché” (market) today.
ATOX receives Letter of Appreciation from Ministry of Economy, Trade and Industry
On April 16, 2019, the ATOX Fukushima Reconstruction Branch was awarded a Letter of Appreciation by the Ministry of Economy, Trade and Industry.
Three “site caravan” events held
Since November 2018 ATOX has held three “site caravans” for nuclear power company customers.
Joint research agreements concluded for regulatory approval of 68Ga-PSMA
On October 31, 2018, ATOX signed joint research agreements with Hokkaido University and Sumitomo Heavy Industries, Ltd. aimed at the regulatory approval of 68Ga-PSMA, a drug with the potential to deliver more effective diagnosis and treatment of prostate cancer.
ATOX wins exclusive sales rights for Galli Eo®
On February 27, 2018, ATOX signed an agreement with IRE ELiT (Belgium) giving ATOX the exclusive rights to sell the 68Ge/68Ga generator drug Galli Eo® in Japan.
R&D on lead-212 (212Pb) generator launched
On November 30, 2017, ATOX signed a joint research agreement with Riken and commenced R&D on lead-212 (212Pb) generators for use in radio isotope (RI) internal radiation therapy with α-ray emission, a promising new kind of cancer treatment.